Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple
(Reuters) -Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity, the California-based company said on Wednesday.
Deep Apple discovers drug candidates using its AI-based platform that screens virtual libraries of billions of compounds to cut drug discovery time, the company said.
Under the deal, Novo will receive exclusive global rights to develop and commercialize so-called non-incretin oral therapies, which belong to a different class of medicines than its popular weight-loss and diabetes drugs Wegovy and Ozempic.
WHY IT'S IMPORTANT
Novo has been trying to strengthen its foothold in the potential $150 billion weight-loss drug market through the development of next-generation treatments as well as acquisitions and partnerships.
In March, the company signed two licensing deals and gained access to experimental obesity drugs from Lexicon Pharmaceuticals and China-based United Laboratories International.
CONTEXT
Novo in May ousted CEO Lars Fruergaard Jorgensen over concerns the Danish company - a world leader in the lucrative weight-loss drug market - was losing its first-mover advantage.
The company's shares have plunged since hitting a record high in June last year as competition, particularly from U.S. rival Eli Lilly, eats into its market share, while Novo's pipeline of new drugs has failed to impress investors.
BY THE NUMBERS
As part of the license agreement with Novo, Deep Apple will be eligible to receive up to $812 million in payments, as well as potential royalties on sales of any products that emerge from their collaboration.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
10 minutes ago
- Miami Herald
Popular nationwide beauty chain files for Chapter 11 bankruptcy
The beauty industry has faced economic challenges and financial distress over the last five years since the Covid-19 pandemic temporarily derailed most retail industries. Companies have dealt with rising labor and product costs exacerbated by inflation, increased interest rates, cautious consumers who are watching their budgets in uncertain economic times, and fierce competition. Don't miss the move: Subscribe to TheStreet's free daily newsletter Some of the biggest names in the beauty business suffered from the Covid-19 fallout and filed for bankruptcy protection, including Revlon, which filed for Chapter 11 bankruptcy in June 2022, and Avon, which filed for Chapter 11 bankruptcy in August 2024. Related: Popular local Dairy Queen rival files for Chapter 11 bankruptcy Beauty technology company Cutera filed for a prepackaged Chapter 11 bankruptcy on March 5, 2025, to reduce its debt by $400 million, and award-winning cosmetics company SBLA Beauty filed for Chapter 11 protection on March 11, 2025, to reorganize its business and restructure its debt. Also, telehealth company Hims & Hers Health shut down its acne treatment dermatology business, Apostrophe, also on March 7, 2025, after buying the San Francisco-based company four years ago for about $190 million. The company, however, did not file for bankruptcy protection. Hims & Hers transitioned away from the Apostrophe brand and encouraged patients to try its brand's treatment options, the company revealed on its website. Another skincare brand Futurewise Inc. revealed that it discontinued orders on its website beginning March 24, 2025. "Goodbye for now," the skincare brand wrote on its website. "After a lot of thought, we have made the hard decision to sunset Futurewise. Futurewise, which offered its skincare products Slug Boost, Slug Cream, Slug Balm, and Face Melt, for its "slugging" practice of skincare, also did not file for bankruptcy. In addition to skin care products, spa services for weight loss, non-surgical body improvements, slimming, and toning are also a major part of the beauty industry. One beauty service chain in Tuscaloosa, Ala., faced severe financial issues, filed for bankruptcy, and closed its business. Medical spa Body Oasis filed for bankruptcy on Nov. 6, 2024, and shut down all of its operations, reportedly leaving customers in limbo, ABC-33/40 News reported. Finally, national spa services chain Contour Spa LLC filed for Chapter 11 bankruptcy protection to reorganize its business, facing significant debt obligations. Related: Huge auto parts company files for Chapter 11 bankruptcy The Orlando, Fla.-based company filed its petition in the U.S. Bankruptcy Court for the Middle District of Florida on June 11, while at least 23 affiliates filed their petitions the following day. More bankruptcy: Iconic auto repair chain franchise files Chapter 11 bankruptcyPopular beer brand closes down and files Chapter 7 bankruptcyPopular vodka and gin brand files for Chapter 11 bankruptcy The debtor listed $500,000 to $1 million in assets and $1 million to $10 million in liabilities in its petition, including over $562,000 owed to Lanco Equities, over $344.000 owed to Kash Advance LLC, over $339,000 owed to Formentera Capital Group, over $377,000 owed to Liberta Funding LLC, and over $239,000 owed to American Express. The company has authorized CEO Roger A. Farwell to seek approval of a debtor-in-possession financing agreement, according to RK Consultants. Contour Spa offers its Cryo Slimming sessions using its slimming and toning protocols designed to reduce cellulite, tighten skin, achieve permanent fat loss, and minimize stretch marks. The spa service also offers its Cryo Facials, which can be obtained for free through its $99 introductory offer, according to its website. Related: Major trucking company files Chapter 11 bankruptcy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
TechCrunch
13 minutes ago
- TechCrunch
After a string of successes, early-stage fund Felicis raises fresh $900M
In Brief Felicis founder Aydin Senkut is celebrating his 20th year as an institutional early-stage investor by announcing the firm's biggest fund yet: a $900 million Fund X. This follows the $825 million Fund IX raised in 2023 and the $600 million Fund XIII raised in 2021. Felicis, a seed and Series A firm, is known for backing a long string of successes, including Ayden, Bonobos, Ring, Shopify, and Twitch, among others. Since being founded in 2006, Felicis has backed over 50 unicorns and had over 125 exits, it says. Lately, Felicis, like most VCs, has been all over AI. Its portfolio now includes, for example, Browser Use, Poolside, Runway, and Supabase. 'We believe dozens of $100B+ AI companies will emerge this decade (not merely $1B or $10B),' Felicis wrote in its blog post, adding that 70% of its active portfolio are what it considers AI native startups. Senkut did not immediately respond to a request for additional comment.
Washington Post
14 minutes ago
- Washington Post
China grants rare earth export permits after US trade talks, offers relief but uncertainty persists
OMAHA, Neb. — The high-level negotiations over China's export controls of rare earths is giving U.S. businesses some relief, even though it may be only for now. China has approved 'a certain number' of export permits for rare earth elements and related items, its commerce ministry said on Thursday, one day after U.S. President Donald Trump declared that Beijing would supply to the U.S. companies those key elements and the magnets made from them following a two-day trade talk in London .
